Jun 1, 2024, 10:17
Hidehito Horinouchi: HARMONi-A – Chemo +/- Ivonescimab in EGFRm NSCLC after EGFR-TKIs resistance
Hidehito Horinouchi, Oncologist at the Department of Thoracic Oncology at the National Cancer Center Hospital, recently shared a post on X:
“ASCO24 Abstracts
No. 8508 HARMONi-A: Chemo +/- Ivonescimab (AK112/SMT112, anti-PD-1/VEGF bispecific ab) in EGFRm NSCLC after EGFR-TKIs resistance
Presenter: Dr. Li Zhang
- PFS HR 0.46 (95%CI: 0.34, 0.62),
- Phase III,
- Primary PFS,
- NCT05184712.”
Source: Hidehito Horinouchi/X